TCR and CD28 Activate the Transcription Factor NF-κB in T-cells Via Distinct Adaptor Signaling Complexes
Overview
Affiliations
The transcription factor NF-κB is needed for the induction of inflammatory responses in T-cells. Whether its activation by the antigen-receptor and CD28 is mediated by the same or different intracellular signaling pathways has been unclear. Here, using T-cells from various knock-out (Cd28(-/-), adap(-/-)) and knock-in (i.e. Cd28 Y-170F) mice in conjunction with transfected Jurkat T-cells, we show that the TCR and CD28 use distinct pathways to activate NF-κB in T-cells. Anti-CD28 ligation alone activated NF-κB in primary and Jurkat T-cells as measured by NF-κB reporter and EMSA assays. Anti-CD28 also activated NF-κB normally in primary T-cells from adap(-/-) mice, while anti-CD3 stimulation required the adaptor ADAP. Over-expression of ADAP or its binding partner SKAP1 failed to enhance anti-CD28 activation of NF-κB, while ADAP greatly increased anti-CD3 induced NF-κB activity. By contrast, CD28 activation of NF-κB depended on GRB-2 binding to CD28 as seen in CD28 deficient Jurkat T-cells reconstituted with the CD28 YMN-FM mutant, and in primary T-cells from CD28 Y170F mutant knock-in mice. CD28 associated with GRB-2, and GRB-2 siRNA impaired CD28 NF-κB activation. GRB-2 binding partner and guanine nucleotide exchange factor, VAV1, greatly enhanced anti-CD28 driven activation of NF-κB. Further, unlike in the case of anti-CD28, NF-κB activation by anti-CD3 and its cooperation with ADAP was strictly dependent on LAT expression. Overall, we provide evidence that CD28 and the TCR complex regulate NF-κB via different signaling modules of GRB-2/VAV1 and LAT/ADAP pathways respectively.
Inhibition of B cell receptor signaling induced by the human adenovirus species D E3/49K protein.
Hildenbrand A, Cramer P, Bertolotti M, Kaiser N, Klasener K, Nickel C Front Immunol. 2024; 15:1432226.
PMID: 39139562 PMC: 11321000. DOI: 10.3389/fimmu.2024.1432226.
Liang L, Yang Y, Deng K, Wu Y, Li Y, Bai L Cells. 2024; 13(13.
PMID: 38995014 PMC: 11240780. DOI: 10.3390/cells13131163.
Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression.
Sirpilla O, Sakemura R, Hefazi M, Huynh T, Can I, Girsch J Nat Biomed Eng. 2024; 8(4):443-460.
PMID: 38561490 DOI: 10.1038/s41551-024-01195-6.
A systems and computational biology perspective on advancing CAR therapy.
Tserunyan V, Finley S Semin Cancer Biol. 2023; 94:34-49.
PMID: 37263529 PMC: 10529846. DOI: 10.1016/j.semcancer.2023.05.009.
Toward high-throughput engineering techniques for improving CAR intracellular signaling domains.
Butler S, Hartman C, Huang Y, Ackerman M Front Bioeng Biotechnol. 2023; 11:1101122.
PMID: 37051270 PMC: 10083361. DOI: 10.3389/fbioe.2023.1101122.